15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
5 citations
,
April 2019 in “Dermatologic therapy” Secukinumab for psoriasis unexpectedly caused increased hair growth in a patient.
May 2022 in “Голова и шея.” Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
September 2023 in “Journal of the American Academy of Dermatology”
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
3 citations
,
October 2018 in “Journal of cosmetic dermatology” Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
Belimumab may cause hair loss in lupus patients.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
10 citations
,
October 2011 in “Dermatologica Sinica” A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
8 citations
,
January 2024 in “Microorganisms” Dupilumab improves skin microbiome balance in atopic dermatitis patients.
April 2024 in “DAHUDER Medical journal” Ocrelizumab may cause pancreatitis in some patients.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
January 2026 in “SKIN The Journal of Cutaneous Medicine” Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.